We are currently enrolling patients in the following studies:
• DIABETIC MACULAR EDEMA
• WET MACULAR DEGENERATION TREATMENT NAÏVE
• WET MACULAR DEGENERATION WITH PRIOR TREATMENT
• GEOGRAPHIC ATROPHY SECONDARY TO MACULAR DEGENERATION
• OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION
Allergan 1833-201-407
Protocol Title: A Phase 1/2 Study to Evaluate the Safety and Efficacy of AGN-193408 SR in
Participants with Open-Angle Glaucoma or Ocular Hypertension
AGN-193408 SR in the treatment of open-angle glaucoma or ocular hypertension
Apellis
APL2-GA-305 PEGCETACOPLAN (APL-2)
A Phase 3, Open-Label, Multicenter, Extension Study to Assess Safety and Efficacy of Pegcetacoplan in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)
IONIS GOLDEN | IONIS PHARMACEUTICALS, INC.
ISIS 696844-CS5
A Phase 2, Randomized, Placebo-Controlled, Double-Masked Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRX, an Antisense Inhibitor of Complement Factor B, in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)
Iveric ISEE2008
A Phase 3, Randomized, Placebo-Controlled, Double-Masked, Sham controlled Clinical Trial to Assess Safety and Efficacy of, INTRAVITREAL ADMINISTRATION OF ZIMURA™
(COMPLEMENT C5 INHIBITOR) in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)
PROTOCOL NO: ISEE2008
GATHER2
OPTHEA
A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the
Efficacy and Safety of Intravitreal OPT-302 in Combination with
Aflibercept, Compared with Aflibercept Alone, in Participants with
Neovascular Age-related Macular Degeneration (nAMD)
Protocol Number:
OPT-302-1005
Regeneron
VGFTe HD DME 1934
Randomized, Double-Masked, Active-Controlled Phase 2/3 Study
to Assess Safety and Efficacy of Multiple Doses of AFLIBERCEPT in patients with Diabetic Macular Edema.
SANDOZ
Protocol CSOK583A12301
A 52-week Multicenter, Randomized, Double-masked, 2-arm parallel study to compare efficacy, safety and immunogenicity of SOK583A1 to Eylea®, administered intravitreally, in patients with neovascular age-related Macular Degeneration
Special thanks to those who have participated in our studies.
For our valued patients that have recently participated in our clinical studies, thank you so much for helping us with recent approvals of:
• EYLEA FOR WET MACULAR DEGENERATION AND CRVO
• BEOVU FOR WET MACULAR DEGENERATION
• LUCENTIS FOR DIABETIC MACULAR EDEMA
• OZURDEX FOR DIABETIC MACULAR EDEMA
• UPNEEQ FOR DROOPY EYELID
• DUREZOL FOR USE AFTER OCULAR SURGERY
• OMIDRIA FOR CATARACT SURGERY
• DURYSTA FOR GLAUCOMA
• ZIOPTAN FOR GLAUCOMA
• SIMBRINZA FOR GLAUCOMA
• TRAVATAN Z FOR GLAUCOMA